Factors associated with mucoid transition of Pseudomonas aeruginosa in cystic fibrosis patients. 2010

B Martha, and D Croisier, and A Fanton, and K Astruc, and L Piroth, and F Huet, and P Chavanet
Service des Maladies Infectieuses, Centre Hospitalier Universitaire, Dijon, France. benoit.martha@wanadoo.fr

Although the mucoid form of Pseudomonas aeruginosa (Pa) is largely responsible for the progression of lung disease in cystic fibrosis (CF), the relationship between factors relating daily-care regimes to mucoidy acquisition are as yet poorly investigated. Fifty-two CF patients registered at the CF centre of Dijon, France, were retrospectively evaluated from the date of Pa colonization either to the first positive sputum culture for mucoid Pa (n = 26) or to the last culture in which the Pa remained non-mucoid (n = 26). All clinical, pathological and therapeutic events were recorded. The association between the parameters collected and mucoid transition of Pa was assessed in a Cox model with time-dependant covariables. The mean follow-up was 4.7 + or - 4.3 years. Three independent parameters were associated with the higher risk of mucoid transition of Pa: persistence of Pa in sputum (OR 7.89; p <0.01), use of inhaled bronchodilators (OR 3.40; p = 0.04), and the use of inhaled colimycin (OR 4.04; p = 0.02). Isolation of Staphylococcus aureus, Haemophilus influenzae or Streptococcus pneumoniae in sputum was associated with a lower risk (OR 0.24; p < 0.01). Mucoid transition of Pa was associated with variables that reflected the severity of both lung disease and Pa colonization. Although they do not lead to prophylactic measures, these results corroborate the need to avoid Pa persistence.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D011135 Polysaccharides, Bacterial Polysaccharides found in bacteria and in capsules thereof. Bacterial Polysaccharides
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D005260 Female Females
D005602 France A country in western Europe bordered by the Atlantic Ocean, the English Channel, the Mediterranean Sea, and the countries of Belgium, Germany, Italy, Spain, Switzerland, the principalities of Andorra and Monaco, and by the duchy of Luxembourg. Its capital is Paris. Corsica,Saint Pierre and Miquelon,Miquelon and Saint Pierre,Miquelon and St. Pierre,St. Pierre and Miquelon

Related Publications

B Martha, and D Croisier, and A Fanton, and K Astruc, and L Piroth, and F Huet, and P Chavanet
March 1982, Australian paediatric journal,
B Martha, and D Croisier, and A Fanton, and K Astruc, and L Piroth, and F Huet, and P Chavanet
October 1991, Nihon rinsho. Japanese journal of clinical medicine,
B Martha, and D Croisier, and A Fanton, and K Astruc, and L Piroth, and F Huet, and P Chavanet
November 2012, Pediatric pulmonology,
B Martha, and D Croisier, and A Fanton, and K Astruc, and L Piroth, and F Huet, and P Chavanet
October 1987, Microbiological sciences,
B Martha, and D Croisier, and A Fanton, and K Astruc, and L Piroth, and F Huet, and P Chavanet
January 2019, Respiratory medicine,
B Martha, and D Croisier, and A Fanton, and K Astruc, and L Piroth, and F Huet, and P Chavanet
May 1984, Journal of clinical microbiology,
B Martha, and D Croisier, and A Fanton, and K Astruc, and L Piroth, and F Huet, and P Chavanet
June 2010, Pediatric pulmonology,
B Martha, and D Croisier, and A Fanton, and K Astruc, and L Piroth, and F Huet, and P Chavanet
January 1992, APMIS. Supplementum,
B Martha, and D Croisier, and A Fanton, and K Astruc, and L Piroth, and F Huet, and P Chavanet
January 1992, Thorax,
B Martha, and D Croisier, and A Fanton, and K Astruc, and L Piroth, and F Huet, and P Chavanet
October 2007, Microbiology (Reading, England),
Copied contents to your clipboard!